| 000 | 01415 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250513074757.0 | ||
| 264 | 0 | _c19930615 | |
| 008 | 199306s 0 0 eng d | ||
| 022 | _a0022-202X | ||
| 024 | 7 |
_a10.1111/1523-1747.ep12472344 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChan, S C | |
| 245 | 0 | 0 |
_aIncreased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. _h[electronic resource] |
| 260 |
_bThe Journal of investigative dermatology _cMay 1993 |
||
| 300 |
_a681-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_a4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone _xpharmacology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCyclic AMP _xmetabolism |
| 650 | 0 | 4 |
_aDermatitis, Atopic _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-4 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aMonocytes _xmetabolism |
| 650 | 0 | 4 |
_aPhosphodiesterase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aPhosphoric Diester Hydrolases _xmetabolism |
| 650 | 0 | 4 | _aReference Values |
| 700 | 1 | _aLi, S H | |
| 700 | 1 | _aHanifin, J M | |
| 773 | 0 |
_tThe Journal of investigative dermatology _gvol. 100 _gno. 5 _gp. 681-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/1523-1747.ep12472344 _zAvailable from publisher's website |
| 999 |
_c8387279 _d8387279 |
||